Ezetimibe effectively lowers LDL-cholesterol in cardiac allograft recipients on stable statin therapy

Clinical Transplantation

Volumn 22, Issue 5, 2008, Pages 639-644

  Konstandin, Mathias H ^a   Blessing, Erwin ^a   Doesch, Andreas ^a   Ammon, Kerstin ^a   Koch, Achim ^b   Wabnitz, Guido H ^b   Gleissner, Christian A ^a   Remppis, Andrew ^a   Katus, Hugo A ^a   Dengler, Thomas J ^a  

^a KH Bayreuth   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cardiac allograft recipients; Efficacy; Ezetimibe

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN A; EZETIMIBE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PREDNISONE; RAPAMYCIN; SIMVASTATIN; STEROID; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONGESTIVE CARDIOMYOPATHY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; LABORATORY TEST; MALE; NAUSEA; PRIORITY JOURNAL; RECIPIENT; STOMACH PAIN;

AZETIDINES; CHOLESTEROL, LDL; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; FEMALE; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 52649135527     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00838.x     Document Type: Article

References (28)

1. Bilchick KC, Henrikson CA, Skojec D, Kasper EK, Blumenthal RS. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J 2004: 148: 200.
2. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Keck BM, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: Twenty-first official adult heart transplant report -2004. J Heart Lung Transplant 2004: 23: 796.
3. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999: 341: 498.
4. Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol 2006: 98: 18P.
5. Wenke K, Meiser B, Thiery J et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003: 107: 93.
6. Kashani A, Phillips CO, Foody JM et al. Risks associated with statin therapy: A systematic overview of randomized clinical trials. Circulation 2006: 114: 2788.
7. Bergman AJ, Burke J, Larson P et al. Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. J Clin Pharmacol 2006: 46: 321.
8. Koshman SL, Lalonde LD, Burton I, Tymchak WJ, Pearson GJ. Supratherapeutic response to ezetimibe administered with cyclosporine. Ann Pharmacother 2005: 39: 1561.
9. Sudhop T, Lutjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002: 106: 1943.
10. Bergman AJ, Burke J, Larson P et al. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J Clin Pharmacol 2006: 46: 328.
11. Kohnle M, Pietruck F, Kribben A, Philipp T, Heemann U, Witzke O. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant 2006: 6: 205.
12. Puthenparumpil JJ, Keough-Ryan T, Kiberd M, Lawen J, Kiberd BA. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc 2005: 37: 1033.
13. Patel AR, Ambrose MS, Duffy GA, Cote H, De Nofrio D. Treatment of hypercholesterolemia with ezetimibe in cardiac transplant recipients. J Heart Lung Transplant 2007: 26: 281.
14. Kendrach MG, Kelly-Freeman M. Approximate equivalent rosuvastatin doses for temporary statin interchange programs. Ann Pharmacother 2004: 38: 1286.
15. Grace KA, Swiecki J, Hyatt R et al. Implementation of a therapeutic-interchange clinic for HMG-CoA reductase inhibitors. Am J Health Syst Pharm 2002: 59: 1077.
16. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998: 81: 582.
17. Terrell AR, Daly TM, Hock KG et al. Evaluation of a no-pretreatment cyclosporin A assay on the Dade Behring dimension RxL clinical chemistry analyzer. Clin Chem 2002: 48: 1059.
18. Vogl M, Weigel G, Seebacher G, Griesmacher A, Laufer G, Muller MM. Evaluation of the EMIT Mycophenolic Acid Assay from Dade Behring. Ther Drug Monit 1999: 21: 638.
19. Dosch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. Clin Ther 2006: 28: 893.
20. Buchanan C, Smith L, Corbett J, Nelson E, Shihab F. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006: 6: 770.
21. Langone AJ, Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation 2006: 81: 804.
22. Catapano A, Brady WE, King TR, Palmisano J. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: A meta-analysis of pooled data from 14 clinical trials. Curr Med Res Opin 2005: 21: 1123.
23. Kerzner B, Corbelli J, Sharp S et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003: 91: 418.
24. Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002: 90: 1084.
25. Pearson TA, Denke MA, McBride PE et al. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: A substudy of the ezetimibe add-on to statin for effectiveness trial. Mayo Clin Proc 2006: 81: 1177.
26. Kastelein JJP, Akdim F, Stroes ESG et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Eng J Med 2008: 358: 1431.
27. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005: 44: 467.
28. Demichelis B, Bobbio M, Donegani E, Di Summa M, Brusca A. The lipid profile after heart transplantation in relation to the preoperative cholesterolemia and to the main pathology. Cardiologia 1993: 38: 241.